{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:23:58Z","timestamp":1771881838101,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Ovarian Cancer"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.cloc.2011.04.003","type":"journal-article","created":{"date-parts":[[2011,5,21]],"date-time":"2011-05-21T09:17:27Z","timestamp":1305969447000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent M\u00fcllerian Carcinoma"],"prefix":"10.1016","volume":"4","author":[{"given":"Neil S.","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan G.","family":"Duda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"di Tomaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Ancukiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn N.","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha A.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cloc.2011.04.003_bib1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib2","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib3","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.seminoncol.2006.03.015","article-title":"The role of gemcitabine in first-line treatment of advanced ovarian carcinoma","volume":"33","author":"Thigpen","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1023\/A:1012556627852","article-title":"Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients","volume":"12","author":"Misset","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1525-1438.2007.00763.x","article-title":"Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study","volume":"17","author":"Harnett","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cloc.2011.04.003_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000082921","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane","volume":"67","author":"Raspagliesi","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.cloc.2011.04.003_bib8","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cloc.2011.04.003_bib9","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cloc.2011.04.003_bib10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cloc.2011.04.003_bib11","first-page":"360","article-title":"Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation","volume":"55","author":"Nagy","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.cloc.2011.04.003_bib12","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cloc.2011.04.003_bib13","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib14","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib16","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cloc.2011.04.003_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cloc.2011.04.003_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib20","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"Willett","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib21","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","article-title":"Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"27","author":"Zhu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","article-title":"Biomarkers of response and resistance to antiangiogenic therapy","volume":"6","author":"Jain","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.cloc.2011.04.003_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nprot.2007.111","article-title":"A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood","volume":"2","author":"Duda","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.cloc.2011.04.003_bib25","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1158\/1078-0432.CCR-08-1136","article-title":"Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species","volume":"14","author":"Roy","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cloc.2011.04.003_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/biomet\/93.3.509","article-title":"False discovery control with p-value weighting","volume":"93","author":"Genovese","year":"2006","journal-title":"Biometrika"},{"key":"10.1016\/j.cloc.2011.04.003_bib27","first-page":"456","article-title":"Targeting metastatic colorectal cancer in 2008: a long way from 5-FU","volume":"22","author":"Pohl","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.cloc.2011.04.003_bib28","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/0008-5472.CAN-06-4102","article-title":"Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model","volume":"67","author":"Jain","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cloc.2011.04.003_bib29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.cloc.2011.04.003_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/scientificamerican0108-56","article-title":"Taming vessels to treat cancer","volume":"298","author":"Jain","year":"2008","journal-title":"Sci Am"},{"key":"10.1016\/j.cloc.2011.04.003_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cloc.2011.04.003_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cloc.2011.04.003_bib33","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1200\/JCO.2008.17.0282","article-title":"Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer","volume":"26","author":"Matulonis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib34","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.2005.08.119","article-title":"Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications","volume":"23","author":"Taghian","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cloc.2011.04.003_bib35","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cloc.2011.04.003_bib36","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-09-2099","article-title":"Direct evidence that bevacizumab, an anti\u2013vascular endothelial growth factor antibody, upregulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer","volume":"69","author":"Xu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.cloc.2011.04.003_bib37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cloc.2011.04.003_bib38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2009.24.8021","article-title":"Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?","volume":"28","author":"Duda","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Clinical Ovarian Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1941439011000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1941439011000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:51:17Z","timestamp":1761850277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1941439011000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1941439011000043"],"URL":"https:\/\/doi.org\/10.1016\/j.cloc.2011.04.003","relation":{},"ISSN":["1941-4390"],"issn-type":[{"value":"1941-4390","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent M\u00fcllerian Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Ovarian Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cloc.2011.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}